Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy for signet ring cell gastric/GEJ adenocarcinoma
NCT07091227Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Peking Union Medical College Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07091227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091227.